Drug General Information
Drug ID	D0KC5X
Former ID	DIB013920
Drug Name	S-18616
Indication	Pain [ICD9: 338, 356.0, 356.8,780; ICD10:G64, G90.0, R52, G89]		Terminated	[546405]
Company	Servier
Structure		Download 2D MOL 3D MOL
Canonical SMILES	N1=C(OCC21Cc1c(CC2)cccc1Cl)N
CAS Number	CAS 162280-52-6
Target and Pathway
Target(s)	Alpha-2A adrenergic receptor	Target Info	Modulator	[525915]
KEGG Pathway	cGMP-PKG signaling pathway
	Neuroactive ligand-receptor interaction
PANTHER Pathway	Alpha adrenergic receptor signaling pathway
Reactome	Adrenoceptors
	Adrenaline signalling through Alpha-2 adrenergic receptor
	Adrenaline,noradrenaline inhibits insulin secretion
	G alpha (i) signalling events
	G alpha (z) signalling events
	Surfactant metabolism
WikiPathways	Monoamine GPCRs
	GPCRs, Class A Rhodopsin-like
	Platelet Aggregation (Plug Formation)
	Integration of energy metabolism
	GPCR ligand binding
	GPCR downstream signaling
References
Ref 546405	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007941)
Ref 525915	S18616, a highly potent spiroimidazoline agonist at alpha(2)-adrenoceptors: II. Influence on monoaminergic transmission, motor function, and anxiety in comparison with dexmedetomidine and clonidine. J Pharmacol Exp Ther. 2000 Dec;295(3):1206-22.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.